Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 342 Results
Inflammatory Disease Healing Data via Palatin’s Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
October 24, 2024
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
October 23, 2024
Palatin Receives Notice of Non-Compliance from NYSE American
October 7, 2024
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
September 26, 2024
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
September 9, 2024
FDA Confirms Acceptability of Palatin’s Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
August 28, 2024
Page 4 of 35